~~<i id='4379142A86'><strike id='4379142A86'><tt id='4379142A86'><pre id='4379142A86'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：leisure time 2025-09-06 06:43:42 Page View：7267

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Stanford president’s abrupt resignation sparks debate
Next article： What does generative AI mean for health care? We asked experts

knowledge

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Sanders wants to replace patents with prizes for drug inventions

SenatehealthcommitteeChairBernieSanders(I-Vt.)wantstorewardnewmedicineswithprizemoney.JoseLuisMagana

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Microsoft's Peter Lee: Generative AI could help doctors be more human

AlexHogan/STATGenerativeAIishavingamoment.PeterLee,whooverseesMicrosoft’sapproachtohealthcareandco-a

WSS

focus

focus

Featured Speakers

explore

knowledge

Microsoft's Peter Lee: Generative AI could help doctors be more human